MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 125280 | Name: Sofpironium tosylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sofpironium, also known as BBI-4000, belongs to a class of drugs called ‘anticholinergics,’ which exert their effect by blocking the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including the activation of sweat glands. Soft-anticholinergics, such as sofpironium, exert their action topically and are rapidly metabolized into a considerably less active metabolite when they reach the blood system, thus potentially allowing for effective doses to be used while reducing the limiting systemic side effects associated with other drugs in this class.

Chemical Structure

Sofpironium tosylate
Sofpironium tosylate
CAS#2409055-48-5 (tosylate)

Theoretical Analysis

MedKoo Cat#: 125280

Name: Sofpironium tosylate

CAS#: 2409055-48-5 (tosylate)

Chemical Formula: C29H39NO8S

Exact Mass: 0.0000

Molecular Weight: 561.69

Elemental Analysis: C, 62.01; H, 7.00; N, 2.49; O, 22.79; S, 5.71

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
1628251-49-9 (cation) 1628106-94-4 (bromide) 2409055-48-5 (tosylate)
Synonym
Sofpironium tosylate; Sofpironium; BBI-4000 ion; BBI-4000 cation; Sofpironium cation;
IUPAC/Chemical Name
(3R)-3-((R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium tosylate
InChi Key
HKOLUULUFDVPNB-JOFREBOKSA-M
InChi Code
InChI=1S/C22H32NO5.C7H8O3S/c1-3-27-20(24)16-23(2)14-13-19(15-23)28-21(25)22(26,18-11-7-8-12-18)17-9-5-4-6-10-17;1-6-2-4-7(5-3-6)11(8,9)10/h4-6,9-10,18-19,26H,3,7-8,11-16H2,1-2H3;2-5H,1H3,(H,8,9,10)/q+1;/p-1/t19-,22+,23?;/m1./s1
SMILES Code
C[N+]1(CC(OCC)=O)C[C@H](OC([C@@](O)(C2CCCC2)C3=CC=CC=C3)=O)CC1.[O-]S(=O)(C4=CC=C(C)C=C4)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 561.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Funato M, Iwata R, Iimoto M. Efficacy of 5% sofpironium bromide gel in Duchenne muscular dystrophy with palmoplantar hyperhidrosis: A retrospective case study. J Dermatol. 2024 Jan;51(1):135-139. doi: 10.1111/1346-8138.16990. Epub 2023 Oct 5. PMID: 37795807. 2: Amano Y, Mazda J, Amano K, Ohi K, Shioiri T. Efficacy of sofpironium bromide gel on clozapine-induced hypersalivation in patients with treatment-resistant schizophrenia: double-blind, controlled crossover study. BJPsych Open. 2023 Jan 13;9(1):e14. doi: 10.1192/bjo.2022.630. PMID: 36636808; PMCID: PMC9885354. 3: Wong NS, Adlam TM, Potts GA, Farshchian M. Hyperhidrosis: A Review of Recent Advances in Treatment with Topical Anticholinergics. Dermatol Ther (Heidelb). 2022 Dec;12(12):2705-2714. doi: 10.1007/s13555-022-00838-3. Epub 2022 Nov 3. PMID: 36329359; PMCID: PMC9674821. 4: Kisielnicka A, Szczerkowska-Dobosz A, Purzycka-Bohdan D, Nowicki RJ. Hyperhidrosis: disease aetiology, classification and management in the light of modern treatment modalities. Postepy Dermatol Alergol. 2022 Apr;39(2):251-257. doi: 10.5114/ada.2022.115887. Epub 2022 May 9. PMID: 35645673; PMCID: PMC9131949. 5: Fujimoto T, Okatsu H, Miyama H. Two-week prospective observational study of 5% sofpironium bromide gel in Japanese patients with primary axillary hyperhidrosis. J Dermatol. 2022 Jun;49(6):594-599. doi: 10.1111/1346-8138.16384. Epub 2022 Apr 8. Erratum in: J Dermatol. 2022 Aug;49(8):800. doi: 10.1111/1346-8138.16511. PMID: 35394087; PMCID: PMC9321746. 6: Armstrong A, Reddy R, Chadha D, Kircik L. SUPPLEMENT ARTICLE: A Novel Drug Delivery Method: Retrometabolic Drug Design. J Drugs Dermatol. 2022 Apr 1;21(4):s5-s10. PMID: 35389593. 7: Gregoriou S, Tsiogka A, Kontochristopoulos G, Offidani A, Campanati A. Sofpironium bromide: an investigational agent for the treatment of axillary hyperhidrosis. Expert Opin Investig Drugs. 2022 Jan;31(1):15-21. doi: 10.1080/13543784.2022.2017880. Epub 2021 Dec 22. PMID: 34890517. 8: Fujimoto T, Abe Y, Igarashi M, Ishikoh A, Omi T, Kanda H, Kitahara H, Kinoshita M, Nakasu I, Hattori N, Horiuchi Y, Maruyama R, Mizutani H, Murakami Y, Watanabe C, Kume A, Hanafusa T, Hamaguchi M, Yoshioka A, Egami Y, Matsuo K, Matsuda T, Akamatsu M, Yorozuya T, Takayama S, Yokozeki H. A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. J Dermatol. 2021 Aug;48(8):1149-1161. doi: 10.1111/1346-8138.15927. Epub 2021 May 26. PMID: 34041788; PMCID: PMC8453842. 9: Hobart J, Burke L, Kirsch B, Chadha D. Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax): Evaluation of Measurement Performance. J Drugs Dermatol. 2021 Apr 1;20(4):410-418. doi: 10.36849/JDD.2021.5569. PMID: 33852243. 10: Gregoriou S, Campanati A, Rigopoulos D, Maria Offidani A, Stratigos A, Kontochristoulos G. Investigational topical anticholinergics in clinical development for the treatment of hyperhidrosis. Expert Opin Investig Drugs. 2021 May;30(5):479-482. doi: 10.1080/13543784.2021.1900114. Epub 2021 Apr 16. PMID: 33691553. 11: Yokozeki H, Fujimoto T, Abe Y, Igarashi M, Ishikoh A, Omi T, Kanda H, Kitahara H, Kinoshita M, Nakasu I, Hattori N, Horiuchi Y, Maruyama R, Mizutani H, Murakami Y, Watanabe C, Kume A, Hanafusa T, Hamaguchi M, Yoshioka A, Egami Y, Matsuo K, Matsuda T, Akamatsu M, Yorozuya T, Takayama S. A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. J Dermatol. 2021 Mar;48(3):279-288. doi: 10.1111/1346-8138.15668. Epub 2021 Jan 7. PMID: 33410265; PMCID: PMC7986147. 12: Paik J. Sofpironium Bromide: First Approval. Drugs. 2020 Dec;80(18):1981-1986. doi: 10.1007/s40265-020-01438-1. PMID: 33236266. 13: Buchwald P. Soft drugs: design principles, success stories, and future perspectives. Expert Opin Drug Metab Toxicol. 2020 Aug;16(8):645-650. doi: 10.1080/17425255.2020.1777280. Epub 2020 Jun 20. PMID: 32476535. 14: Bodor M. Új lágy gyógyszerek kifejlesztése és klinikai sikere [Development and clinical success of novel soft drugs]. Orv Hetil. 2020 Mar;161(10):363-373. Hungarian. doi: 10.1556/650.2020.31657. PMID: 32115992. 15: Kirsch B, Smith S, Cohen J, DuBois J, Green L, Baumann L, Bhatia N, Pariser D, Liu PY, Chadha D, Walker P. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial. J Am Acad Dermatol. 2020 Jun;82(6):1321-1327. doi: 10.1016/j.jaad.2020.02.016. Epub 2020 Feb 15. PMID: 32068049.

View History

Metronidazole disodium phosphate

Metronidazole disodium phosphate